X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used for the development of company's portfolio of novel intellectual property assets, including ALA-002 (3,4-methylenedioxymethamphetamine), which is under investigation for the treatment of PTSD and social anxiety in autistic adults.
Lead Product(s): Midomafetamine
Therapeutic Area: Psychiatry/Psychology Product Name: ALA-002
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $0.7 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 19, 2024
Details:
The net proceeds will be used for the development of company's portfolio of novel intellectual property assets, including ALA-002 (3,4-methylenedioxymethamphetamine), which is under investigation for the treatment of PTSD and social anxiety in autistic adults.
Lead Product(s): Midomafetamine
Therapeutic Area: Psychiatry/Psychology Product Name: ALA-002
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $0.7 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 10, 2024
Details:
The agreement aims for the clinical phase development of ALA-002 which under investigation for the treatment of post-traumatic stress disorder (PTSD) and social anxiety in autistic adults.
Lead Product(s): ALA-002
Therapeutic Area: Psychiatry/Psychology Product Name: ALA-002
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: University of Sydney
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 20, 2023
Details:
The Company intends to use the net proceeds to fund phase 2 clinical trials of the Company’s patented ALA series of molecules including, ALA-002, an oral, small molecule drug being developed for the treatment of social anxiety disorder and post-traumatic stress disorder.
Lead Product(s): ALA-002
Therapeutic Area: Psychiatry/Psychology Product Name: ALA-002
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement June 12, 2023
Details:
Psilocybin reacts agonistically with serotonin (5-hydroxytryptamine) type 2A (5-HT2A) receptors to produce a “mystical-like” hallucinatory effect due to induced frontal hyper-frontality, which in turn mediates its anti-depressant and anti-anxiety effects.
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 03, 2023
Details:
Under the sales agreement, PharmAla will be the exclusive global reseller of Mindset’s cGMP (i.e. pharmaceutical grade) psilocybin to appropriately licensed clinical researchers.
Lead Product(s): Psilocybine
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Recipient: Mindset Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 16, 2022
Details:
PharmAla’s goal is to bring ALA-002 into the clinic as a treatment for disorders in adults diagnosed with Autism Spectrum Disorder (ASD). ALA-002 was tested not only in general population research, but also in generally accepted autism mouse models.
Lead Product(s): ALA-002
Therapeutic Area: Neurology Product Name: ALA-002
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
